BPC-157 + TB-500 Blend
Research Material
- AreaRecovery
- CAS137525-51-0 (BPC-157); 77591-33-4 (TB-500 / Thymosin Beta-4)
- Purity≥99%
from$99.95
View Material →
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide comprising a partial sequence of a protein originally isolated from human gastric juice. With the amino-acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular formula C62H98N16O22 and a monoisotopic-scale molecular weight of approximately 1419.5 g/mol, it is catalogued under CAS 137525-51-0 and PubChem CID 9941957. The compound is notably stable in aqueous and acidic environments relative to many peptides, a property that has made it a frequent subject in gastrointestinal and connective-tissue research.
In the peer-reviewed literature, BPC-157 has been studied extensively in rodent injury models addressing tendon, ligament, muscle, bone and mucosal repair. Proposed mechanisms center on modulation of angiogenesis (via VEGFR2 and the nitric-oxide / eNOS-Akt axis), fibroblast activity and collagen organization. Helio supplies BPC-157 as a lyophilized powder in 5 mg and 10 mg vials for laboratory research applications. This material is offered for Research Use Only and is not for human or veterinary use.
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV)
Research use only — not for human or animal consumption. Per-batch documentation is provided with the material.
Preclinical work led largely by Sikiric, Seiwerth, Brcic and colleagues reports that BPC-157 accelerates healing across multiple rodent tissue-injury paradigms, with vascular and nitric-oxide pathways recurring as central mechanistic themes. Documented endpoints include enhanced angiogenesis and VEGF expression, improved tendon and ligament biomechanics, and mucosal protection in gastrointestinal models.
These observations derive from animal and in-vitro experiments; controlled human efficacy has not been established, and no receptor has been definitively identified. All data should be interpreted within an experimental, hypothesis-generating context.
BPC-157 was derived in the 1990s from Body Protection Compound (BPC), a peptide fraction identified in human gastric juice, and has since been characterized across an extensive series of experimental studies (also referenced as PL 14736 in earlier inflammatory-bowel research). It remains an unapproved investigational compound used strictly for laboratory research.
View compound profile on NIH PubChem →
Cited literature refers to laboratory and preclinical research. BPC-157 is supplied strictly for research use only and is not intended to diagnose, treat, cure, or prevent any disease.
